Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT ID: NCT02968368

Last Updated: 2020-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 167 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-01
• Study Completion Date: 2018-10-10

Brief Summary

To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD

Conditions

Renal Insufficiency, Chronic; Iron-Deficiency Anemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Oral ferric maltol

30mg capsules BID

Group Type: EXPERIMENTAL

Ferric maltol

Intervention Type: DRUG

Oral placebo

Matching placebo capsules BID

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Interventions

Ferric maltol

Intervention Type: DRUG

Placebo

Intervention Type: OTHER

Other Intervention Names

Feraccru

Eligibility Criteria

Inclusion Criteria

1. Ability to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved information sheet and consent form. Must sign and date the informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations prior to any study mandated procedure.

2. Willing and able to comply with study requirements.

3. Age ≥ 18 years at the time of informed consent.

4. A current diagnosis of CKD with an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m2 and ≥15 mL/min/1.73m2, as calculated using the abbreviated version of the Modified Diet in Renal Disease equation (MDRD) assessed via screening laboratory results.

5. Iron deficiency anemia defined by the following criteria assessed via screening laboratory results:

1. Hb <11.0g/dL and ≥8.0g/dL

2. AND ferritin <250ng/mL with a Transferrin saturation (TSAT) <25% OR ferritin <500ng/mL with a TSAT of <15%

6. Female subjects of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, a vasectomized partner and oral contraceptive medications. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as no menstrual period within 1 year of screening) are also allowed to participate.

Exclusion Criteria

1. Anemia due to any cause other than iron deficiency, including, but not limited to:

1. Untreated or untreatable severe malabsorption syndrome.

2. Myelosuppression use (permitted if taken at a stable dose and frequency for at least 12 weeks prior to randomization and are expected to stay stable throughout the double-blind treatment period so long as there is no clinical evidence of the myelosuppression contributing to the subject's anemia).

2. Administration with any of the following prior to randomization:

1. IV iron injection within the previous 4 weeks or administration of intramuscular or depot iron preparation within the previous 12 weeks.

2. Single agent oral iron supplementation, taken specifically to treat anemia (e.g. ferrous sulfate, fumarate and gluconate) within the previous 2 weeks. Multivitamins are permitted.

3. Use if ferric citrate and sucroferric oxyhydroxide within the previous 1 week.

4. ESAs within the previous 4 weeks

5. Blood transfusion or donation within the previous 12 weeks.

6. Dimercaprol or cloramphenicol within the previous 7 days.

7. Current use of methyldopa.

3. Currently receiving dialysis or initiation of dialysis is considered likely during the study.

4. Renal transplant within 12 months prior to randomization or is considered likely during the study.

5. Known hypersensitivity or allergy to the active substance or excipients of ferric maltol or placebo capsules.

6. Contraindication for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anemia, thalassemia, or lead intoxication induced anemia.

7. Impaired liver function as indicated by alanine aminotransferase (ALT) or aspartate transaminase (AST) > 3 times the upper limit of normal as assessed via screening laboratory results.

8. Clinically significant vitamin B12 or folic acid deficiency as determined by the screening laboratory results (retest following at least 2 weeks of starting treatment with vitamin B12 or folate replacement is permitted).

9. Pregnant or breast feeding.

10. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anemia; for example coagulation disorders or recurrent GI bleeding.

11. Scheduled or expected major surgery during the course of the study. (Minor surgeries not associated with significant blood loss, in the Investigator's judgement, are permitted e.g. surgery related to fistulae or vascular access, minor dental extractions, incision and drainage of abscess or simple excisions).

12. Participation in any other interventional clinical study within 30 days prior to screening.

13. Cardiovascular, liver, renal, hematologic, psychiatric, neurologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject.

14. Any other unspecified reason that, in the opinion of the Investigator or the Sponsor make the subject unsuitable for enrolment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shield Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Sampson, MBChB

Role: STUDY_DIRECTOR

Shield Therapeutics

Locations

Peoria, Arizona, United States

Phoenix, Arizona, United States

Prescott, Arizona, United States

Tucson, Arizona, United States

La Mesa, California, United States

Long Beach, California, United States

Roseville, California, United States

Sacramento, California, United States

Denver, Colorado, United States

Coral Springs, Florida, United States

Edgewater, Florida, United States

Lauderdale Lakes, Florida, United States

Miami, Florida, United States

Macon, Georgia, United States

Shreveport, Louisiana, United States

Pontiac, Michigan, United States

Roseville, Michigan, United States

Las Vegas, Nevada, United States

Asheville, North Carolina, United States

Charlotte, North Carolina, United States

Wilmington, North Carolina, United States

Bethlehem, Pennsylvania, United States

Knoxville, Tennessee, United States

Nashville, Tennessee, United States

El Paso, Texas, United States

San Antonio, Texas, United States

Hampton, Virginia, United States

Countries

United States

References

Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis. 2021 Dec;78(6):846-856.e1. doi: 10.1053/j.ajkd.2021.03.020. Epub 2021 May 23.

Reference Type: DERIVED

PMID: 34029682 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

ST10-01-303

Identifier Type: -

Identifier Source: org_study_id